In order to obtain the mesenchymal stem cells for myocardial regeneration it is absolutely necessary to develop specific antibodies for the surface antigens of the target cells.

The purpose of this study is the production and purification of specific antibodies from the hybridomas lines, which allows the obtaining of large amounts of antibodies, at a lower price, compared to the antibodies now in use. The laboratory production of the monoclonal anti CD45 antibodies from the hybridomas lines were monitored, as well as the antibodies that are used for the negative selection of mesenchymal stem cells, in order to obtain a large amount of purified cells. The working method consists of: the cells harvested from the bone marrow were put in contact with these antibodies, which are bound to the cells presenting on their surface the CD45 antigen. Furthermore, by adding complement fraction, these cells are damaged, except for the negative CD45 cells and mesenchymal stem cells. Thus, a large amount of pure mesenchymal stem cells can be produced, and they are used in the next phase. Then, the cells are maintained viable using a bioreactor, which will ensure a dynamic medium that allows long survival of isolated cells.